Related Experiment Videos
Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy
D J Cartwright1, A L Cole, A J Cousins
1Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.
Journal of Inherited Metabolic Disease
|December 25, 2004
Abstract:
Fabry disease patients have increased risk of vascular disease despite cardioprotective increased HDL-cholesterol. Enzyme therapy does not significantly alter the lipid profile in the short term.